摘要
自身淋巴细胞生物学疗法是一种可以门诊施行的治疗晚期恶性肿瘤的过继免疫疗法。其主要程序是输注体外用抗CD3单克隆抗体等活化的,用甲氰咪胍和低剂量γ射线等去除或抑制T抑制细胞活性的自身淋巴细胞。病人同时服用甲氰咪胍以去除或抑制体内T抑制细胞的活性。作者共治疗患者65例,217人次,除10例18人次在回输时有轻微类似输液反应的寒颤伴暂时的轻度体温升高外,未见其它毒性反应。对其中37例输注治疗3次以上的病人,进行临床疗效分析,缓解率(CR+PR)为24%,有效率(CR+PR+MR)为51%。自身淋巴细胞生物学疗法疗效与文献报道的LAK疗法相似,但费用低廉,副作用和毒性较低。
AbstractAutolymphocyte biotherapy is an
adoptive cellular therapy based upon the infusion of autolo-gous
lymphocytes that have been activated in vitro by anti-CD3 monoclonal
antibody and depletedof suppressor T cells by cimetidine,indomethacin
and low dose of γ irradiation. The patients alsoreceive oral
cimetidine to block suppressor T cell activity in vivo. Sixty five
patients received 217autolymphocyte infusions and toxicity was
minimal with transient fever and chill accompanying 18ifusions.The
efficacy of treatment in patients received more than 3 infusions were
evaluated.In37 evaluable patients,the response rate(CR +PR)was
24%(9/37 ).As the side reactions aremild,the treatment can be done on
an outpatient basis.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1995年第6期464-466,共3页
Chinese Journal of Oncology
基金
河南省科委科技攻关